Skip to content
← Back to explorer

Toward Closed-loop Molecular Discovery via Language Model, Property Alignment and Strategic Search

Junkai Ji, Zhangfan Yang, Dong Xu, Ruibin Bai, Jianqiang Li, Tingjun Hou, Zexuan Zhu · Dec 10, 2025 · Citations: 0

Data freshness

Extraction: Stale

Check recency before relying on this page for active eval decisions. Use stale pages as context and verify against current hub results.

Metadata refreshed

Mar 11, 2026, 3:30 PM

Stale

Extraction refreshed

Mar 11, 2026, 3:30 PM

Stale

Extraction source

Persisted extraction

Confidence unavailable

Abstract

Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability. Recent advances in generative modelling, including autoregressive, diffusion, and flow-based approaches, have enabled de novo ligand design beyond the limits of enumerative screening. Yet these models often suffer from inadequate generalization, limited interpretability, and an overemphasis on binding affinity at the expense of key pharmacological properties, thereby restricting their translational utility. Here we present Trio, a molecular generation framework integrating fragment-based molecular language modeling, reinforcement learning, and Monte Carlo tree search, for effective and interpretable closed-loop targeted molecular design. Through the three key components, Trio enables context-aware fragment assembly, enforces physicochemical and synthetic feasibility, and guides a balanced search between the exploration of novel chemotypes and the exploitation of promising intermediates within protein binding pockets. Experimental results show that Trio reliably achieves chemically valid and pharmacologically enhanced ligands, outperforming state-of-the-art approaches with improved binding affinity (+7.85%), drug-likeness (+11.10%) and synthetic accessibility (+12.05%), while expanding molecular diversity more than fourfold. By combining generalization, plausibility, and interpretability, Trio establishes a closed-loop generative paradigm that redefines how chemical space can be navigated, offering a transformative foundation for the next era of AI-driven drug discovery.

Low-signal caution for protocol decisions

Use this page for context, then validate protocol choices against stronger HFEPX references before implementation decisions.

  • Structured extraction is still processing; current fields are metadata-first.

HFEPX Relevance Assessment

Signal extraction is still processing. This page currently shows metadata-first guidance until structured protocol fields are ready.

Best use

Background context only

Use if you need

A provisional background reference while structured extraction finishes.

Main weakness

Structured extraction is still processing; current fields are metadata-first.

Trust level

Provisional

Eval-Fit Score

Unavailable

Eval-fit score is unavailable until extraction completes.

Human Feedback Signal

Not explicit in abstract metadata

Evaluation Signal

Weak / implicit signal

HFEPX Fit

Provisional (processing)

Extraction confidence: Provisional

Field Provenance & Confidence

Each key protocol field shows extraction state, confidence band, and data source so you can decide whether to trust it directly or validate from full text.

Human Feedback Types

provisional

None explicit

Confidence: Provisional Source: Persisted extraction inferred

No explicit feedback protocol extracted.

Evidence snippet: Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Evaluation Modes

provisional

None explicit

Confidence: Provisional Source: Persisted extraction inferred

Validate eval design from full paper text.

Evidence snippet: Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Quality Controls

provisional

Not reported

Confidence: Provisional Source: Persisted extraction inferred

No explicit QC controls found.

Evidence snippet: Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Benchmarks / Datasets

provisional

Not extracted

Confidence: Provisional Source: Persisted extraction inferred

No benchmark anchors detected.

Evidence snippet: Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Reported Metrics

provisional

Not extracted

Confidence: Provisional Source: Persisted extraction inferred

No metric anchors detected.

Evidence snippet: Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Rater Population

provisional

Unknown

Confidence: Provisional Source: Persisted extraction inferred

Rater source not explicitly reported.

Evidence snippet: Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Human Data Lens

Structured extraction is still processing. Below are provisional signals inferred from abstract text only.

  • Potential human-data signal: No explicit human-data keywords detected.
  • Potential benchmark anchors: No benchmark names detected in abstract.
  • Abstract highlights: 3 key sentence(s) extracted below.

Evaluation Lens

Evaluation fields are currently inferred heuristically from abstract text.

  • Potential evaluation modes: No explicit eval keywords detected.
  • Potential metric signals: No metric keywords detected.
  • Confidence: Provisional (metadata-only fallback).

Research Brief

Deterministic synthesis

Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Generated Mar 11, 2026, 3:30 PM · Grounded in abstract + metadata only

Key Takeaways

  • Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.
  • Recent advances in generative modelling, including autoregressive, diffusion, and flow-based approaches, have enabled de novo ligand design beyond the limits of enumerative screening.
  • Yet these models often suffer from inadequate generalization, limited interpretability, and an overemphasis on binding affinity at the expense of key pharmacological properties, thereby restricting their translational utility.

Researcher Actions

  • Compare this paper against nearby papers in the same arXiv category before using it for protocol decisions.
  • Check the full text for explicit evaluation design choices (raters, protocol, and metrics).
  • Use related-paper links to find stronger protocol-specific references.

Caveats

  • Generated from abstract + metadata only; no PDF parsing.
  • Signals below are heuristic and may miss details reported outside the abstract.

Recommended Queries

Related Papers

Papers are ranked by protocol overlap, extraction signal alignment, and semantic proximity.

No related papers found for this item yet.

Need human evaluators for your AI research? Scale annotation with expert AI Trainers.